Website Notice Block
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________________
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16 of the
Securities Exchange Act of 1934
For the month of October 2014
Commission File Number: 001-36349
MediWound Ltd.
(Translation of registrant’s name into English)
42 Hayarkon Street
Yavne, 8122745 Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F x Form 40-F o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): __
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): __
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes o No x
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): ________
EXPLANATORY NOTE
On October 29, 2014, MediWound Ltd. issued a press release entitled “MediWound to Host Third Quarter 2014 Financial Results Conference Call on November 5, 2014 at 4:30 p.m. Eastern Time”. A copy of this press release is furnished as Exhibit 99.1 herewith.
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
MEDIWOUND LTD.
|
|||
|
Date: October 29, 2014
|
By: |
/s/ Sharon Malka
|
|
|
Name: Sharon Malka
|
|||
|
Title: Chief Financial Officer
|
|||
3
EXHIBIT INDEX
| Exhibit | Description |
|
99.1
|
Press release dated October 29, 2014 titled “MediWound to Host Third Quarter 2014 Financial Results Conference Call on November 5, 2014 at 4:30 p.m. Eastern Time”.
|
4
|
|
Exhibit 99.1
|
|
News Release
|
|
MediWound to Host Third Quarter 2014 Financial Results Conference
Call on November 5, 2014 at 4:30 p.m. Eastern Time
|
|
YAVNE, Israel (October 29, 2014) – MediWound Ltd. (Nasdaq: MDWD), a fully-integrated, biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release financial results for the three and nine months ended September 30, 2014, after the market close on Wednesday, November 5, 2014.
|
|
Following the release, MediWound's management will host a conference call for the investment community beginning at 4:30 p.m. ET on Wednesday, November 5, 2014, to discuss the financial results and to answer questions.
|
|
Shareholders and other interested parties may participate in the conference call by dialing (877) 602-7189 (domestic) or (678) 894-3057 (international) and entering passcode 26917687. The call also will be broadcast live on the Internet at www.streetevents.com and www.mediwound.com.
|
|
A replay of the call will be accessible two hours after its completion through November 11, 2014 by dialing (855) 859-2056 (domestic) or (404) 537-3406 (international) and entering passcode 26917687. The call will also be archived for 90 days at www.streetevents.com and www.mediwound.com.
|
|
About MediWound Ltd.
|
|
MediWound is a fully integrated biopharmaceutical company focused on developing, manufacturing and commercializing novel therapeutics based on its patented proteolytic enzyme technology to address unmet needs in the fields of severe burns, chronic and other hard-to-heal wounds. MediWound’s first innovative biopharmaceutical product, NexoBrid, received marketing authorization from the European Medicines Agency for removal of dead or damaged tissue, known as eschar, in adults with deep partial and full-thickness thermal burns and was launched in Europe. NexoBrid represents a new paradigm in burn care management, and clinical trials have demonstrated, with statistical significance, its ability to non-surgically and rapidly remove the eschar earlier and, without harming viable tissues. For more information, please visit www.mediwound.com.
|
|
Contacts:
|
Anne Marie Fields
|
|
Sharon Malka
|
Senior Vice President
|
|
CFO
|
LHA
|
|
MediWound
|
212-838-3777
|
|
ir@mediwound.co.il
|
afields@lhai.com
|